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PAIN IN PARKINSON’S DISEASE
Analysis of 50 cases in a clinic of movement disorders
Elton Gomes da Silva1, Maura Aparecida Viana2,  
Elizabeth Maria Aparecida Barasnevicius Quagliato3
Abstract – Introduction: Pain is a common symptom in Parkinson’s disease (PD), and is often related to the illness 
itself.  Objective: To prospectively establish the ocurrence of pain in PD patients.  Method: This study was 
conducted within a population composed of 50 patients with PD to evaluate the presence of pain.  Results: 
Twenty-eight patients reported pain; comparing the group with pain and the group without pain, there were 
no differences related to the beginning of the illness and the motor symptoms of PD. However, many patients 
related an improvement of pain when antiparkinsonian therapy was initiated or adjusted.  Conclusion: The use 
of techniques for analgesia and the adjustment of PD medication contribute to improve the manifestations 
of pain and the life quality of patients with PD.
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Dor na doença de Parkinson: análise de 50 casos em uma clínica de transtornos do movimento
Resumo – Introdução: Dor é um sintoma comum na doença de Parkinson (DP) e, às vezes, está relacionada 
à própria patologia de base.  Objetivos: Estabelecer prospectivamente a ocorrência de dor em pacientes 
com DP.  Método: Foram avaliados consecutivamente 50 pacientes com DP, para comparação entre os que 
referiam e os que negavam quadro álgico.  Resultados: Entre os entrevistados, 28 referiam episódios dolorosos, 
não havendo diferenças quanto ao início da doença e os sintomas motores da DP, na comparação entre 
os dois grupos. Porém, muitos pacientes referiam melhora da dor com a introdução ou ajuste da terapia 
antiparkinsoniana.  Conclusão: O uso de analgesia e ajuste da terapia para a DP ajudam na melhora do quadro 
álgico e na qualidade de vida dos pacientes.
PALAVRAS-CHAVE: doença de Parkinson, dor, fisiopatologia, tratamento.
Department of Neurology, Medical Science School, State University of Campinas, São Paulo SP, Brazil (FCM/UNICAMP) : 1MD, Student in Neurosurgery; 
2MD; 3MD, PhD, Adjunct Professor, responsible for the Movement Disorders Unit, Teaching Hospital, UNICAMP. Support: State of São Paulo Research 
Foundation (FAPESP).
Received 27 June 2007, received in final form 18 September 2007. Accepted 19 November 2007.
Dr. Elton Gomes da Silva – Departamento de Neurologia / FCM/UNICAMP - Caixa Postal 6111 - 13083-970 Campinas SP  - Brasil. E-mail: elgosi@ 
yahoo.com.br
In century XIX, Charcot had already discovered a rela-
tion between Parkinson idiopathic disease (PD) and pain. 
This was related to parkinsonian symptoms or due to 
rheumatologic modifications resulting from a more ad-
vanced age, demonstrating that the effects of this disease 
are not limited to cognitive and motor aspects1-4.
Pain as a primary symptom is usually located on the 
side of the body that is most compromised by the disease, 
suggesting a relation to modifications of the cerebral neu-
rotransmission, mainly on the basal ganglia. In addition, 
pain usually appears prematurely in patients, and can ap-
pear before the occurrence of motor symptoms, and is 
therefore not recognized as a symptom of PD until fur-
ther symptoms appear. Pain disappears when the disease 
is finally diagnosed and treated4-6. The main motor symp-
tom related to pain is rigidity, which occurs frequently on 
the “off” episodes, i.e. during the period in which the an-
tiparkinsonian medication loses its effect until the next 
administration of the doses. In more advanced stages of 
the disease, an instability of the therapeutic effect oc-
curs, occasioning a loss of the effect of the medication 
during the “on” period, which is entitled “wearing-off” ef-
fect, and during this period the symptoms of pain can be 
emphatic2,3,5,7. The treatment always demands a great ad-
justment of dopamine agonist, local injections of steroids, 
massages, physiotherapy and analgesic therapy, which im-
prove the life quality of patients8-10.
The objective of this prospective study was to estab-
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lish the frequency of pain among these patients, in addi-
tion to seeking clinical characteristics and pharmacologi-
cal therapy that could be related to pain manifestations.
METHOD
During the period July 2004 to March 2005, 50 patients with 
PD diagnosis were interviewed, consecutively followed up at 
the Movement Disorders Outpatient Unit of the Department 
of Neurology, State University of Campinas Teaching Hospital 
(HC/UNICAMP). The PD diagnoses were based on the criteria 
of London Brain Bank11.
The patients were submitted to a questionnaire, compris-
ing their epidemiologic data and motor symptoms. The clini-
cal analysis was conducted using the UPDRS (Unified Parkinson’s 
Disease Rating Scale)12 for the subscales I (mental state, behav-
ior and humor), II (daily routine activities), III (motor examina-
tion), IV (therapy complications), Hoehn and Yahr’s staging; and 
the Schwab and England’s scale (classifying the patient’s depen-
dence on a caretaker for daily routine activities, being defined 
in dependence percent).
Patients with painful symptoms were submitted to a ques-
tionnaire in which pain was evaluated, as well as the numerical 
graduation of pain (a scale of 1–10, in which 1 represented the 
less possible pain, and 10 represented the maximum possible 
pain) before and after the administration of medication.
This study was approved by the Research Ethics Commit-
tee of the Medical Science School of the UNICAMP, and the pa-
tients were informed as to the objectives of the evaluation, and 
signed a consent term.
The percentage and average calculations as well as the chi-
square test were used for the statistics when indicated.
RESULTS
Among the 50-interviewed patients, 34 (68%) were 
men and 16 (32%) women, presenting the initial clinical 
manifestations of PD with an average age of 53.2±10.3 
years, ranging from 31 to 74 years old. The time elapsed 
from the origin of the symptoms and the interview was 
8.7±5.2 years (ranged from 1 to 22 years).
Resting tremor was observed in 42 patients (84%), ri-
gidity in 41 (82%), bradykinesia in 44 (88%), and modifica-
tion of postural reflexes in seven patients (14%).
The medication used by these patients in monother-
apy or in association to improve the parkinsonian symp-
toms were levodopa and dopamine agonist.
Twenty-eight (56%) patients – 12 women and 16 men – 
reported the presence of pain; Table 1 show the relation 
between the patients with and without pain in the gender, 
age, time of PD history, main symptoms of disease (trem-
or, rigidity and bradykinesia) and use of main medication 
to PD. There was not statistically significant difference be-
tween these patients.
The manifestation of pain in 28 patients ranged from 
one to 30 years (average of 8.3±6.7 years); however, some 
patients (12) manifested pain before manifestating PD 
symptoms.
Table 2 show the type of pain among the patients, 
and unspecified pain was a gastrointestinal pain in burn-
ing and was not related the parkinsonian symptoms. Dys-
tonia was a pain with primary origin, related with rigidi-
ty or bradykinesia.
Pain episodes occurred daily in 16 (57.1%) patients, two 
patients (7.1%) presented more than one episode a month, 
and nine patients (32.1%) presented pain sporadically; one 
patient presented pain only during the “off” periods. 
Among the 28 patients with pain, 78.6% used mainly 
nonhormonal and anti-inflammatory analgesics. One pa-
tient used amitriptyline and 14.3% of the patients with pain 
Table 1. Relation in patients with or without pain.
Pain Presence Absence
Male 16 18
Female 12 4
Age 53.6±10.9 52.6±9.8
Time of PD symptoms 8.8±5.8 8.5±4.4
Resting tremor 24 18
Rigidity 21 20
Bradykinesia 25 19
Use of levodopa 21 18
Use of dopamine agonist 6 8
p>0.05 compared among patients with or without pain.
Table 2. Frequency of patients in every type of pain.
Pain Total  (%)
Muscle-skeletal 14 (50.0)
Dystonia 6 (21.4)
Radicular 3 (10.7)
Articular 2 (7.1)
Headache 2 (7.1)
Unspecified 1 (2.6)
Table 3. Frequency of patients in every classification of Hoenh 
and Yahr’s stage, according to presence or absence of pain.
Hoehn and Yahr / Pain Presence Absence Total
1.0 2 0 2
1.5 5 1 6
2.0 5 5 10
2.5 6 7 13
3.0 4 8 12
4.0 6 1 7
p>0.05 compared among patients with or without pain.
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underwent other analgesic methods (gabapentin, carbam-
azepine, opioids, acupuncture, and physiotherapy). Only 
one patient used no analgesic at all during periods of pain.
There was a significant improvement of pain during 
the effect of the antiparkinsonian medication in eight 
patients (28.6%), i.e. during the “on” period, and pain in-
creased during the “off” period. Seven patients used le-
vodopa and three used dopamine agonist.
The degree of pain, considering a numerical scale of 
0–10 (being 10 for the maximum possible pain), was of 
6.1±1.8 points before the use of medication and, of 3.3±2.3 
after medication therapy. There was a significant differ-
ence in the improvement of pain with the administration 
of medication (p<0.05), however a comparison of self-giv-
en scores among the patients using medication and those 
not using was not possible as only one patient claimed no 
to make use of any analgesic treatment.
The total score in the UPDRS scale was of 52.0±24.0; 
therefore, there was no statistically significant difference 
among the patients with or without pain (p=0.41), as ob-
served in Table 3.
Analyzing the UPDRS parameters separately, we ob-
served a statistical significance regarding patients with 
pain, who complained of having a greater difficulty of get-
ting and walking in relation to the patients without pain, 
p=0.00430 and p=0.00435, respectively.
According to the Schwab and England’s scale, which 
classifies the patient’s dependence on a caretaker for dai-
ly activities, there was no statistically significant differ-
ence between patients with or without pain, despite the 
degree of dependence.
DISCUSSION
The frequency of pain in patients with PD ranges from 
30 to 70% according to the literature2-4,13-15, and was also 
observed in this study, which revealed a 56% of patients 
with pain. There was no statistically significant difference 
related to gender.
The age of patients with pain did not differ from those 
without pain, in contrast to other studies2,6, where pa-
tients presenting pain were younger, in age addition, there 
was no difference between the two groups of patients 
(with/without pain)at the moment when parkinsonian 
signs appeared. But these studies did not explicate the 
cause of this difference, so pain is more evident in pa-
tients with rigidity and/or akynesia and they are older.
There was no difference in the presence of clinical 
signs between the patients with or without pain; therefore 
there was no relation between motor and sensory symp-
toms, despite the fact that patients with pain claimed to 
have a greater difficulty to get dressed or walk, with a 
significant difference between the groups.
This difference was not made clear on the motor anal-
ysis by UPDRS, which was similar between the patients 
with and without pain, as observed in a recent study16, 
contrary to two previous studies17,18 that demonstrated 
motor fluctuations between the groups with and with-
out complaints of pain.
Contrary to other studies2,7,17, we found only one pa-
tient asserting that pain occurred only during the “off” pe-
riod of medication, 28.5% of the patients with pain claimed 
to feel better when using the antiparkinsonian medica-
tion, similar to previous studies6,12, suggesting that pain 
could be occurring due to the “wearing-off” effect, but 
the improve was relate to the correct use of medication.
The most frequent manifestation reported was mus-
cle-skeletal pain, with a daily frequency, which could be 
improved or not with the use of medication; this mani-
festation was characterized having a rheumatologic ori-
gin as pain was not related to the period of effect of the 
antiparkinsonian medication.
Rare forms of pain, such as comprising oral or genital 
parts19, were not observed in our study, and that was not 
used other medications, like subcutaneous apomorphine, 
that shown improve in a case report20.
There was no difference among the self-given score for 
the Schwab and England’s scale regarding daily-life activi-
ties between the patients with or without pain, although 
some reports demonstrated that patients with pain had 
more symptoms of depression15,17, which could reduce the 
graduation in these patients. However, this study did not 
analyze the presence of depression; therefore, it was not 
possible to make a comparison with previous studies5,6,9,10,13.
The patients classified in the Hoehn and Yahr’s stage 
1.0, 1.5, and 5.0 presented pain in 100, 90 and 85 per cent 
of cases, the stage 2.0, 2.5 and 3.0 presented pain in 50 per 
cent or less of cases; that shown the patients in the first 
years of disease had lower pain threshold than in the oth-
er patients, maybe because this patients did not used anti-
parkinsonian medication in the early phase of the disease, 
and in the later phase, the medication was less effective.
None of the patients mentioned aggravation of symp-
toms after using PD medication, however there has been 
one case cited in the literature3.
The physiopathogenic mechanism resulting from this 
scenario is not yet clear like the relation between PD and 
olfactory dysfunction21, however recent studies16,22 points 
out that patients with PD have a lower pain threshold than 
healthy people, highlighting a relation between pain and 
PD. In addition to serotoninergic nociceptive pathways, 
other factors can be involved, such as depression – a com-
mon symptom in these patients23. 
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In conclusion, the manifestation of pain occurs with 
a certain frequency in parkinsonian patients, and these 
manifestations present a significant improvement with the 
use of medication and analgesics used to decrease the 
symptoms of the disease, in addition to the therapeutic 
adjustment of levodopa. The knowledge of the primary 
and secondary causes of PD pain and of the correlation 
with the dose of levodopa allow therapeutic changes that 
could contribute to the improvement of the treatment of 
these patients. The treatment of chronic pain helps pa-
tients improve their performance of daily-life activities, 
as well as their life quality. The pain threshold is lower 
in the earlier and later phases of the disease, when the 
patients use little or have not good response to the use 
of levodopa, that is showing this medication is related in 
the pain way.
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